Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting an Astellas cancer drug for an eye disease that has attracted lots of VC and pharma attention in recent years. Sling Therapeutics ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Novartis' TREM2 drug fails Phase 2 ALS trial endpoints.news